Navigation Links
Nano Mask Enters Into Four-Year Distribution Agreement With Saudi Medical Products Distributor
Date:8/25/2011

FISHKILL, N.Y., Aug. 25, 2011 /PRNewswire/ -- Nano Mask, Inc. (NMI) (Pink Sheets: NANM), a healthcare product development and distribution company focused on emergency and critical care as well as infection control markets, has announced that it has entered into a distribution agreement with a Saudi Arabia-based medical products distributor which will represent NMI's product line on an exclusive basis to: The Kingdom of Saudi Arabia, United Arab Emirates, Kuwait, Egypt, Morocco, Oman, Algeria, Qatar, Jordan, Bahrain, Sudan, Yemen Lebanon, Yemen and Tunisia.

In exchange for four years of exclusive rights to distribute NMI's product line in the Territory, the Saudi Arabian medical products distributor, having already delivered to date over $90,000.00 in orders, has agreed to order a minimum of $ 2,300,000 over the next four years. The products that will be marketed and sold in the Territory are NMI's emergency life support and respiratory products (utilizing the company's industry leading patented 2H Filtration Technology), antimicrobial hospital barrier products and NMI's proprietary line of bacteria free enzymatic medical detergents specially formulated for instrument reprocessing.

"This agreement, which covers 15 Middle Eastern countries, represents the first of what we hope will be many international distribution agreements for our products," said Eddie Suydam, President and CEO, NMI.

Mr. Suydam added, "We are currently in negotiations with other medical products distributors, both domestic and international, to sell our products and expect that we will begin to see some meaningful sales from our marketing efforts in the near future."

About Nano Mask, Inc.

NMI is the inventor of 2H Technology, an advanced dual filtration system which is designed to remove infectious bacteria and virus from airflow systems at extremely high levels of efficiency. In addition to the company's advanced filtration materials and products, NMI also markets a line of innovative infection control products which range from proprietary enzymatic instrument reprocessing solutions to innovative antimicrobial textiles in the United States and internationally.

Forward-looking Statement

This release may contain statements that are forward-looking. Such statements are made based upon current expectations that are subject to risk and uncertainty. Specifically, any unforeseen delays in manufacturing and distribution may affect the planned timeline for initiating actual sales of the product. NMI does not undertake to update forward-looking statements in this news release to reflect actual results of and changes in assumptions or changes in other factors affecting such forward-looking information. The actual future plans and results of the company could differ significantly from such forward-looking statements.

Contact:
For further information:
Ed Suydam  
(914) 760-7857  
eds@nmihealth.com


'/>"/>
SOURCE Nano Mask, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
2. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
3. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
4. Cepheid Announces Termination of Contract With the Centers for Disease Control and Prevention to Develop Rapid Point of Care Test for Avian Influenza
5. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
6. Concentra Medical Centers Gears Up for Flu Season to Keep Area Workforce Healthy
7. Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
8. Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
9. Juvaris BioTherapeutics Announces Cooperative Research and Development Agreement With The Centers for Disease Control and Prevention
10. AcroMetrix Renews Contract With Group Services for Americas Blood Centers
11. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Research ... World Market for Companion Diagnostic Tests" report to their ... Market for Companion Diagnostics The World Market ... and personalized medicine diagnostics. Market analysis in the report includes ... Test Market (In Vitro Diagnostic Kits) by Region (N. America, ...
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology:
(Date:6/26/2016)... , ... June 26, 2016 , ... On June 10-11, ... of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, ... the city’s history as home to some of the world’s leading providers of cereal ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/24/2016)... ... 24, 2016 , ... Those who have experienced traumatic events may suffer from ... avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid this ... coping following a traumatic event. , Trauma sufferers tend to feel a range of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, ... treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including robotic ... osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It ...
Breaking Medicine News(10 mins):